Valuation: Abeona Therapeutics Inc.

Market Cap 425M 369M 345M 315M 593M 40.58B 602M 4.07B 1.59B 20.31B 1.6B 1.56B 67.76B P/E 2026 *
-10.1x
P/E 2027 * -149x
Enterprise Value 425M 369M 345M 315M 593M 40.58B 602M 4.07B 1.59B 20.31B 1.6B 1.56B 67.76B EV / Sales 2026 *
6.55x
EV / Sales 2027 * 3.4x
Free-Float
79.49%
Yield 2026 *
-
Yield 2027 * -
1 day-14.95%
1 week-6.69%
Current month-1.17%
1 month-9.10%
3 months+11.71%
6 months+27.15%
Current year+20.40%
1 week 6.05
Extreme 6.05
7.65
1 month 5.83
Extreme 5.83
7.65
Current year 4.23
Extreme 4.23
7.65
1 year 4
Extreme 4
7.65
3 years 2.88
Extreme 2.88
9.01
5 years 2.19
Extreme 2.19
34
10 years 2.19
Extreme 2.19
568.75
Manager TitleAgeSince
Chief Executive Officer 50 2021-10-14
Director of Finance/CFO 42 2022-03-13
Chief Tech/Sci/R&D Officer - 2025-10-19
Director TitleAgeSince
Director/Board Member 58 2006-02-28
Director/Board Member 64 2021-03-24
Director/Board Member 63 2021-04-18
Date Insider Type Main position Quantity % Market Cap.
7/21/26 Sell

Chief Financial Officer

-1,478 0.0026%
7/9/26 Sell

Executive/Senior Manager

-12,606 0.0221%
7/9/26 Sell

Chief Financial Officer

-24,880 0.0437%
Change 5-day change 1-year change 3-year change Capi.($)
-14.95%-6.69%-0.55%+112.21% 425M
+1.00%+4.86%+44.81%-0.12% 79.68B
+0.97%+4.90%-0.37%+26.99% 50.61B
-1.22%-4.41%+17.13%+167.13% 48.81B
-0.66%+5.25%-47.97%-48.32% 46.91B
+0.85%+1.95%+63.38%-23.03% 30.86B
-0.03%+13.15%+148.05%-37.28% 25.42B
-0.21%+0.60%+47.68%+82.80% 24.48B
-0.42%+5.37%+8.99%+187.03% 21.2B
-3.14%-0.95%+65.43%+161.38% 16.39B
Average -1.64%+3.99%+34.66%+62.88% 34.48B
Weighted average by Cap. +0.09%+2.91%+29.84%+41.40%

Financials

2026 *2027 *
Net sales 64.88M 56.23M 52.72M 48.07M 90.44M 6.19B 91.89M 621M 242M 3.1B 244M 238M 10.34B 125M 109M 102M 92.78M 175M 11.95B 177M 1.2B 468M 5.98B 470M 460M 19.96B
Net income -42.44M -36.79M -34.48M -31.44M -59.16M -4.05B -60.11M -406M -159M -2.03B -159M -156M -6.76B -561K -487K -456K -416K -783K -53.58M -795K -5.37M -2.1M -26.82M -2.11M -2.06M -89.47M
Net Debt - -
Logo Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
226
Date Price Change Volume
26-08-13 US$6.345 -14.95% 4,866,345
26-08-12 US$7.460 +0.81% 2,213,063
26-08-11 US$7.400 -0.67% 2,190,654
26-08-10 US$7.450 +2.90% 1,183,762
26-08-07 US$7.240 +4.93% 1,396,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.460USD
Average target price
19.71USD
Spread / Average Target
+164.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABEO Stock